Integra LifeSciences Holdings Corporation — FY2015 Form 10-K Summary
Business Context and Reporting Period
Integra is a global medical technology company focused on regenerative technologies, specialty surgical solutions, neurosurgery, wound care, extremity orthopedics, tissue repair and surgical instruments. This Form 10-K covers the fiscal year ended December 31, 2015. Following the July 1, 2015 tax-free spin-off of SeaSpine, continuing operations comprise Specialty Surgical Solutions and Orthopedics and Tissue Technologies. Prior periods were recast to present SeaSpine as discontinued operations.
Key Financial Metrics
| Metric | 2015 | 2014 | Change |
|---|---|---|---|
| Revenue | $882.7 million | $796.7 million | Up 11% |
| Gross margin | $556.2 million; 63.0% | $493.8 million; 62.0% | Margin up 100 bps |
| Operating income | $79.6 million | $67.9 million | Up 17% |
| Income from continuing operations | $6.9 million; $0.19 diluted EPS | $36.3 million; $1.10 diluted EPS | Material decline |
| Net income (loss) | $(3.5) million; $(0.10) diluted EPS | $34.0 million; $1.03 diluted EPS | Declined to a loss |
| Operating cash flow from continuing operations | $106.7 million | $58.8 million | Up $47.8 million |
| Cash and cash equivalents | $48.1 million | $71.7 million | Down $23.6 million |
- Specialty Surgical Solutions revenue was $586.9 million, up 6%; Orthopedics and Tissue Technologies revenue was $295.8 million, up 22%.
- U.S. revenue increased 14% to $680.8 million, while international revenue was approximately $201.9 million and was adversely affected by $22.2 million of foreign-exchange impact.
- Operating expenses increased 12% to $476.6 million. Research and development expense was $50.9 million and selling, general and administrative expense was $415.8 million.
- Net interest expense was $23.5 million. The effective income tax rate was 88.7%, primarily because of a $37.2 million non-cash valuation allowance related to deferred tax assets associated with the SeaSpine spin-off.
- Investing cash outflows were $365.0 million, including $328.9 million for acquisitions and $33.4 million for capital expenditures. Financing cash inflows were $258.5 million, including $219.7 million of net proceeds from an equity offering used to repay debt.
Material Changes Versus the Prior Comparable Period
- Revenue growth was driven substantially by acquisitions, including TEI, MicroFrance, Salto and Futura, Tekmed and Metasurg-related contributions, as well as organic growth in dural repair, instruments, regenerative products and shoulder products.
- Gross margin improved because of favorable mix and increased sales of higher-margin DuraSeal, DuraGen, skin and wound products, partly offset by acquisition-related inventory fair-value adjustments and higher technology amortization.
- Profitability was pressured by higher selling, general and administrative costs, research and development investment, acquisition and integration costs, restructuring, ERP implementation costs and the non-cash tax valuation allowance.
- The company completed the SeaSpine separation, resulting in a smaller and less diversified continuing business and a $10.4 million loss from discontinued operations in 2015.
- Goodwill increased to $512.4 million from $363.5 million, primarily due to the TEI and Tekmed acquisitions. No impairment was recorded for the remaining continuing-operations reporting units in 2015.
Guidance, Outlook, Risks and Unusual Items
- Management expected 2016 consolidated gross margin of approximately 64%, research and development expense of 5.5% to 6.0% of revenue, selling, general and administrative expense of 44.5% to 45.0% of revenue, and a worldwide effective tax rate of approximately 26% to 27%.
- Management expected 2016 capital expenditures of $35 million to $40 million, primarily for facility automation, ERP implementation and orthopedic instrument kits.
- The FDA approved the Omnigraft PMA supplement for diabetic foot ulcers on January 7, 2016; commercialization was anticipated in mid-2016.
- The Añasco, Puerto Rico FDA warning letter was closed in January 2015. However, an outstanding FDA warning letter remained related to TEI’s promotion of SurgiMend for unapproved breast-surgery applications. The company stated that it did not expect material operating expenses to complete corrective actions, but further FDA scrutiny remained possible.
- TEI was involved in approximately 50 active product-liability cases. BSC was managing the litigation, TEI had $3.0 million of product-liability insurance retention before BSC indemnification, and Integra had specified merger-agreement indemnification protections.
- The $227.1 million principal amount of 1.625% convertible notes was due in December 2016. The company intended to refinance, extend or use available credit capacity to satisfy the obligation. The senior credit facility had approximately $600 million of available borrowing capacity at year-end, and the company was in compliance with its covenants.
- Key ongoing risks include reimbursement reductions, healthcare cost-containment, regulatory approvals and enforcement, competition, foreign-exchange volatility, reliance on certain suppliers, product liability, acquisition integration, goodwill and intangible-asset impairment, ERP implementation, cybersecurity and the use of bovine-derived materials.
- The 2.3% U.S. medical-device excise tax was suspended for 2016 and 2017 and was scheduled to resume in 2018 absent further legislative action.
Important Facts for Investors to Verify
- Reconcile reported revenue growth with organic growth and acquisition contributions, particularly TEI and MicroFrance, and assess the effect of foreign exchange.
- Evaluate whether the improvement in gross margin and expected 2016 margin expansion is sustainable after acquisition-related inventory adjustments and higher manufacturing costs.
- Review the impact of the $37.2 million non-cash tax valuation allowance and the reasonableness of management’s 2016 tax-rate outlook.
- Assess refinancing and liquidity plans for the December 2016 convertible-note maturity, including interest-rate exposure and credit-facility covenant headroom.
- Monitor the TEI FDA warning letter, product-liability litigation, indemnification coverage and potential uninsured exposure.
- Assess acquisition integration, goodwill of $512.4 million, finite-lived intangible assets of $602.7 million and the sensitivity of impairment testing to projected growth and discount rates.
- Confirm the timing, reimbursement status and commercial performance of Omnigraft and other pipeline products.